Roche ’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan

Roche today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva ®/Gazyvaro® (obinutuzumab) plus chemotherapy followed by Gazyva/Gazyvaro alone head-to-head against MabThera®/Rituxan® (rituximab) plus chemotherapy followed by MabThera/Rituxan alone for people with previously untreated follicular lymphoma.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news